These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 23964827)

  • 1. Increased visfatin in hemodialysis patients is associated with decreased demands for recombinant human erythropoietin.
    Eleftheriadis T; Pissas G; Remoundou M; Antoniadi G; Liakopoulos V; Stefanidis I
    Ren Fail; 2013; 35(10):1399-403. PubMed ID: 23964827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
    Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
    Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol.
    Nüsken KD; Petrasch M; Rauh M; Stöhr W; Nüsken E; Schneider H; Dötsch J
    Nephrol Dial Transplant; 2009 Sep; 24(9):2832-8. PubMed ID: 19389865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients.
    do Sameiro-Faria M; Ribeiro S; Rocha-Pereira P; Fernandes J; Reis F; Bronze-da-Rocha E; Miranda V; Quintanilha A; Costa E; Belo L; Santos-Silva A
    Ren Fail; 2013; 35(10):1392-8. PubMed ID: 23991655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferroportin in monocytes of hemodialysis patients and its associations with hepcidin, inflammation, markers of iron status and resistance to erythropoietin.
    Eleftheriadis T; Pissas G; Remoundou M; Filippidis G; Antoniadi G; Oustampasidou N; Liakopoulos V; Stefanidis I
    Int Urol Nephrol; 2014 Jan; 46(1):161-7. PubMed ID: 23860963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship of visfatin levels to inflammatory cytokines and left ventricular hypertrophy in hemodialysis and continuous ambulatory peritoneal dialysis patients.
    Erten Y; Ebinç FA; Ebinç H; Paşaoğlu H; Demirtaş C; Taçoy G; Koç E; Derici U; Reis KA; Bali M; Arinsoy T; Sindel S
    Ren Fail; 2008; 30(6):617-23. PubMed ID: 18661412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients.
    Kato A; Tsuji T; Luo J; Sakao Y; Yasuda H; Hishida A
    Am J Nephrol; 2008; 28(1):115-21. PubMed ID: 17943020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.
    Axelsson J; Witasp A; Carrero JJ; Qureshi AR; Suliman ME; Heimbürger O; Bárány P; Lindholm B; Alvestrand A; Schalling M; Nordfors L; Stenvinkel P
    Am J Kidney Dis; 2007 Feb; 49(2):237-44. PubMed ID: 17261426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical and economic significance of iron replacement in anemia treated with recombinant human erythropoietin in patients on hemodialysis].
    Vanková S; Safárová R; Horácková M; Herink J; Rychlík I; Bahbouh R; Půtová I
    Cas Lek Cesk; 2001 Apr; 140(7):209-13. PubMed ID: 11374225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of iron requirements during treatment of anemia with recombinant human erythropoietin in patients with chronic renal insufficiency under hemodialysis].
    Oliveira C; Boquinhas H; Gaspar A; Adragão T; Boquinhas JM; Júnior EC; Simões J
    Acta Med Port; 1992 Jul; 5(7):351-7. PubMed ID: 1442178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.
    Fishbane S; Berns JS
    Kidney Int; 2005 Sep; 68(3):1337-43. PubMed ID: 16105069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
    Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
    Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin with oral iron in peritoneal and hemodialysis patients. A comparison in an inner city population.
    Raja R; Bloom E; Goldstein M; Johnson R
    ASAIO J; 1993; 39(3):M578-80. PubMed ID: 8268603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
    Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
    ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
    Raja R; Bloom E; Johnson R
    Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia and carnitine supplementation in hemodialyzed patients.
    Kletzmayr J; Mayer G; Legenstein E; Heinz-Peer G; Leitha T; Hörl WH; Kovarik J
    Kidney Int Suppl; 1999 Mar; 69():S93-106. PubMed ID: 10084293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
    Gallucci MT; Lubrano R; Meloni C; Morosetti M; Manca di Villahermosa S; Scoppi P; Palombo G; Castello MA; Casciani CU
    Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring iron status in end-stage renal disease patients on hemodialysis.
    Rafi A; Karkar A; Abdelrahman M
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.